Breast cancer is the most common cancer in women all over the world. The incidence of breast cancer increases with age, and the highest incidence appears to occur after menopause.

As Roche Turkey, we have implemented a social responsibility project with the slogan of “Meme Kanseri Merakına Yenilsin” (Beat Breast Cancer With Curiosity) and reached more than 2 thousand people in total in 6 provinces, in order to answer the questions in mind about the disease with correct answers and to create social awareness.

For more accurate and up-to-date information about the disease, you can follow the @merakinayenilsin Instagram account, which is the social media leg of the project.

For all the questions you may haveplease visit our account.

Patients with a family history can be candidates for genetic testing. The most common mutations associated with breast cancer are BRCA1 and BRCA2 mutations. Individuals with this mutation are more likely to develop breast cancer.

If there is a palpable mass or a suspicious area, the size of this mass and its relationship with the skin and chest muscles are thoroughly examined. Generally, irregularly demarcated, painless, and firm masses support the presence of a tumor. Other potential signs and symptoms are swelling in one part of the breast, skin irritation, unusual asymmetry, pain and retraction in the nipple, nipple, or rash on the nipple or flaking or discharge. In some cases, the first sign of breast cancer is adenopathy, which usually occurs in the axillary lymph node.

The treatment decision for the patient is made based on the stage and size of the tumor, grade and metastasis potential, HER2 positivity, the patient's physical condition (WHO, Karnofsky scales), the patient's age, preference, and psychological status. Treatment options in breast cancer:

  • Surgery

  • Radiotherapy

  • Hormone treatment

  • Chemotherapy

  • Biological treatment

  • Supportive treatment


  1. Globocan 2008. Cancer facts sheets: breast cancer. Available at: Accessed April 2012.

  2. National Cancer Institute 2012. Surveillance Epidemiology and End Results Stats Fact Sheets: Breast Cancer. Available at:

    Accessed May 2012.

  3. Globocan 2008. Estimated cancer mortality, all ages: Female. Available at:

    Accessed April 2012

  4. Jemal A, et al. Global Cancer Statistics. CA Cancer J Clin 2011; 61:69–90.

  5. American Cancer Society. Breast Cancer. Available at: Accessed April 2012.

  6. Blackwood MA, Weber BL: BRCA1 and BRCA2: from molecular genetics to clinical medicine. J Clin Oncol 1998; 16:1969–1977.

  7. Dent R, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res 2007; 4429:13.

  8. Dent SF. The role of VEGF in triple-negative breast cancer: where do we go from here? Ann Oncol. 2009; 20:1615–1617.

  9. Nishimura R, Arima N. Is triple negative a prognostic factor in breast cancer? Breast Cancer 2008; 15:303–308.

  10. Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist 2011; 16 Suppl 1:1–11.

  11. Edge SB, et al., eds. Breast. In: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, 347–376.

  12. American Cancer Society. Breast Cancer. Available at:

    Accessed April 2012.

  13. NCCN Guidelines Version 1.2012. Available at: Accessed April 2012.

  14. American Society of Clinical Oncology, "Five Things Physicians and Patients Should Question" (PDF), Choosing Wisely: an initiative of the ABIM Foundation (American Society of Clinical Oncology), retrieved 14 August 2012

  15. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Jahanzeb M, Kiel K, Ljung BM, Marcom PK, Mayer IA, McCormick B, Nabell LM, Pierce LJ, Reed EC, Smith ML, Somlo G, Theriault RL, Topham NS, Ward JH, Winer EP, Wolff AC (2009). "Breast cancer. Clinical practice guidelines in oncology". Journal of the National Comprehensive Cancer Network : JNCCN 7 (2): 122–192.

  16. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE (2010). "Aspirin Intake and Survival After Breast Cancer". Journal of Clinical Oncology 28 (9): 1467–72.

  17. Jahanzeb M (August 2008). "Adjuvant trastuzumab therapy for HER2-positive breast cancer". Clin. Breast Cancer 8 (4): 324–33.

  18. Massarut S, Baldassare G, Belleti B, Reccanello S, D'Andrea S, Ezio C, Perin T, Roncadin M, Vaidya JS (2006). "Intraoperative radiotherapy impairs breast cancer cell motility induced by surgical wound fluid"

     J Clin Oncol 24 (18S): 10611.

  19. Belletti B, Vaidya JS, D'Andrea S, Entschladen F, Roncadin M, Lovat F, Berton S, Perin T, Candiani E, Reccanello S, Veronesi A, Canzonieri V, Trovò MG, Zaenker KS, Colombatti A, Baldassarre G, Massarut S (March 2008). "Targeted intraoperative radiotherapy impairs the stimulation of breast cancer cell proliferation and invasion caused by surgical wounding". Clin. Cancer Res. 14 (5): 1325–32.

  20. Hall PS, McCabe C, Stein RC, Cameron D. J Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer. J Natl Cancer Inst. 2012 Jan 4;104(1):56-66.

The information provided on this site is not for diagnostic or medical advice, but for informational purposes. If you have or think you have a disease to be treated, consult a specialist physician.

For adverse events related to Roche products,

To contact us about other issues;

Roche Pharma Address: Roche Müstahzarları San A.Ş. Uniq İstanbul Ayazağa Caddesi No:4D/101 34396 Maslak/İstanbul Tel: +90 212 366 90 00


Roche Diagnostics Address: Roche Diagnostics Turkey A.Ş. Esentepe Mah. Kırgülü Sk. Metrocity İş Merkezi D Bl. No: 4/5 34394 Şişli /İstanbul; Tel: +90 212 306 06 06


Supervisors: Bahar Süral & Naz Kocaoğlu